source
- BMS drops Orum’s targeted degrader after Phase 1 resultsBMS announced it is ending development of ORM-6151, a degrader‑antibody conjugate acquired from Orum Therapeutics. The decision follows a Phase 1 trial in acute myeloid leukemia and myelodysplasti…
- HCA Healthcare sues Independence Blue Cross over $345,000 in unpaid Texas hospital claimsSeveral Texas hospitals owned by HCA Healthcare have filed a lawsuit against Independence Blue Cross, a Philadelphia‑based insurer, seeking more than $345,000 in unpaid medical claims dating back r…